FMP
Alterity Therapeutics Limited
ATHE
NASDAQ
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
3.54 USD
-0.227 (-6.41%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. David A. Stamler M.D.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
CIK
0001131343
ISIN
US02155X2053
CUSIP
02155X106
Address
460 Bourke Street
Phone
61 3 9349 4906
Country
AU
Employee
10
IPO Date
Sep 29, 2003
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ATHE Financial Summary
CIK
0001131343
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
02155X106
ISIN
US02155X2053
Country
AU
Price
3.54
Beta
0.48
Volume Avg.
471.5k
Market Cap
37.86M
Shares
-
52-Week
1-5.87
DCF
-0.01
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.32
P/B
-
Website
https://alteritytherapeutics.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ATHE News
It looks like there's no news available.
